Coloma Therapeutics is developing small-molecule medicines that harness the cell's natural protein-disposal machinery. Its PROSPECTOR discovery platform identifies molecules that bind proteins of interest, helping the team explore new ways to remove harmful proteins and address disease targets that have been difficult to reach with conventional drugs. [1]
An academic spinout from the University of Pittsburgh School of Medicine, Coloma brings its principal investigators and research scientists together as company founders. The team combines expertise in protein biology, screening and computational modeling to expand the range of proteins accessible to targeted degradation and advance new therapeutic programs. [2] [1]